Accessory-Cell-Mediated Activation of Porcine NK Cells by Toll-Like Receptor 7 (TLR7) and TLR8 Agonists |
| |
Authors: | Felix N. Toka Charles K. Nfon Harry Dawson William T. Golde |
| |
Affiliation: | Plum Island Animal Disease Center, ARS, USDA, P.O. Box 848, Greenport, New York 11944,1. Warsaw University of Life Sciences, Faculty of Veterinary Medicine, Department of Preclinical Sciences, Warsaw, Poland,2. Beltsville Area Research Center, ARS, USDA, Beltsville, Maryland 207053. |
| |
Abstract: | The induction of innate immune responses by toll-like receptor (TLR) agonists is the subject of intense investigation. In large part, this reflects the potential of such compounds to be effective vaccine adjuvants. For that reason, we analyzed the activation of innate cells in swine by TLR7 and TLR8 agonists. These agonists activated porcine NK cells by increasing gamma interferon (IFN-γ) expression and perforin storage. The activation of porcine NK cells was mediated by accessory cells, since their depletion resulted in reduced cytotoxicity toward target cells. Accessory cells were stimulated to produce interleukin 12 (IL-12), IL-15, IL-18, and IFN-α after treatment with TLR7 or TLR8 agonists. Neutralization of these cytokines reduced but did not completely inhibit the induction of NK cell cytotoxicity. Direct stimulation of NK cells with TLR7 or TLR8 agonists resulted in minimal cytotoxicity but levels of IFN-γ equivalent to those detected in the presence of accessory cells. Porcine NK cells express both TLR7 and TLR8 mRNAs, and treatment with these TLR agonists induced higher mRNA expression levels of TRAIL and IL-15Rα, which may contribute to the activity of NK cells. These data indicate that TLR7 and TLR8 agonists indirectly or directly activate porcine NK cells but that optimum levels of activation require cytokine secretion by accessory cells activated by these compounds. Interestingly, NK cells activated by TLR7 or TLR8 agonists were cytotoxic against foot-and-mouth disease virus (FMDV)-infected cells in vitro, indicating that these TLR agonists may be beneficial as adjuvants to stimulate the innate immunity against FMDV.Toll-like receptors (TLRs) are pathogen-associated molecular pattern recognition receptors responsible for signaling intrusion by pathogens. These receptors are expressed by cells mediating innate responses. Pathogens are recognized directly by the binding of pathogen-associated molecules. For example, TLR3 recognizes double-stranded RNA during virus replication; TLR5 binds bacterial flagellin; TLR9 detects nonmethylated, CG-rich prokaryotic DNA, i.e., CpG; and TLR7 and TLR8 recognize single-stranded RNA (44), although recognition by TLR8 may be species specific, as demonstrated recently by Forsbach et al. (11). The consequence of engaging TLRs is the induction of signals that lead to the expression of proinflammatory cytokines, antimicrobial and antiviral effector molecules, and costimulatory molecules on macrophages (Mφ) and dendritic cells (DCs) (25, 39). Overall, such events affect the activation and functional status of innate immune cells, such as natural killer (NK) cells and DCs, and further influence the organization of adaptive immune responses.NK cells perform a critical role in innate immunity, leading to protection against various pathogens well before the adaptive immune responses develop. NK cells are lymphocyte-derived cells that engage nonspecific target recognition mechanisms to eliminate malignant or virus-infected cells (10). However, it has recently been shown that some receptors on NK cells engage viral gene products. For example, Ly49H recognizes m157 of murine cytomegalovirus in mice, while NKp44 and NKp46 bind influenza virus hemagglutinin (4, 27). Moreover, NK cells express both inhibitory and activating receptors, which directly influence the outcome of NK cell activation. Besides the expression of such receptors (22), NK cells have other mechanisms that enhance their function as natural spontaneous effector cells (24). Such mechanisms include the expression of TLRs, which possibly allow NK cells to respond to the presence of pathogens by direct activation via these receptors.NK cells express TLR9 in mice (26) and TLR1 to TLR10 in humans (12, 17, 23). However, not much information is currently available on the expression of these receptors on immune cells of domestic livestock species, such as porcine or bovine species. Direct stimulation of human NK cells through TLR2, TLR3, TLR7, and TLR8 leads to the upregulation of gamma interferon (IFN-γ) secretion, although in some instances this response requires the presence of interleukin 12 (IL-12) (6, 12, 17). Furthermore, activation via TLR5 is reported to stimulate NK cell proliferation but not IFN-γ production (45). Additionally, stimulation via TLR2 or TLR7 induces chemokines such as CCL3, CCL4, and CCL5 (36). Although TLR9 is expressed in NK cells, it does not induce IFN-γ production directly unless the NK cells are presented with antibody-coated target cells or are cultured on plates with an immobilized antibody against immunoglobulin G (35). Therefore, TLR expression in NK cells may be involved in the differential regulation of these vital cells of the innate response. However, not much is known about the direct effect of TLR stimulation on the expression of NK cell effector molecules, such as perforin, granzymes, and cytokines.Using this class of molecules, it is now possible to formulate vaccine adjuvants that prime cell-mediated immunity. Engaging TLR receptors with specific synthetic agonists introduces a new way of inducing early innate responses as well as increasing the potency of adaptive immunity. The importance of such an approach is exemplified by several clinical studies currently under way. TLR9 and TLR4 agonist are being tested as vaccine adjuvants, and a TLR7 agonist is being tested in the treatment of genital warts caused by herpes simplex virus (28). In addition, TLR4 is being tested for the treatment of allergies, endotoxemia, and liver disease, TLR7 for cancer treatment, and TLR9 as a treatment for melanoma (reviewed by Ulevitch [46]).Foot-and-mouth disease virus (FMDV) infects cloven-hoofed animals, leading to devastating economic consequences (16). This is a highly contagious viral infection that causes a very acute disease. Clinical symptoms are detected within 1 or 2 days of exposure and resolve within a week to 10 days. Viral clearance may be mediated in part by antibodies, but under controlled experimental conditions, viremia is gone by day 3 or 4 after infection when anti-FMDV immunoglobulin M is barely detectable (2, 13). These results strongly suggest that other antiviral mechanisms contribute to the elimination of the virus in vivo. Innate responses, including the activation of DCs and NK cells, are likely involved.Therapeutic approaches involving TLR stimulation via synthetic agonists can augment innate responses, indicating that such therapeutics have the potential to induce early protection against foot-and-mouth disease (29, 30). Therefore, we have studied the effects of TLR agonists on porcine NK cells in vitro. We report that TLR7 and TLR8 agonists and a combined TLR7/8 agonist activate porcine CD2+ CD8+ CD3− NK cells through accessory-cell-mediated mechanisms, such as the secretion of cytokines, including IFN-α, IL-12, IL-15, and IL-18. In addition, porcine NK cells are partially activated by the direct interaction of TLR7 and TLR8 agonists through these receptors expressed by NK cells. Activated cells show enhanced secretion of IFN-γ and storage of perforin granules and can effectively lyse tumor or FMDV-infected targets. These results are discussed in the context of rational approaches to antiviral measures against FMDV. |
| |
Keywords: | |
|
|